Synopsis
Anti-cancer drugs are beyond the reach of average Indian patients. Early-stage patients spend up to INR6 lakh on medicines alone. For advanced stages, the cost is higher. Scientist Himanshu Gadgil gave up a cushy job in the US and returned to India with a mission. Pioneering a unique manufacturing process, he is changing the game, one drug at a time.
At Amgen’s Thousand Oaks headquarters in California, Himanshu Gadgil had everything that talented young scientists aspire for. In his seven-year stint with the American biotech giant, Gadgil helmed several product-development teams, led interactions with top regulatory agencies, and authored scientific papers. Until fate took a tragic turn. In 2009, Gadgil’s father passed away, having suffered internal bleeding because of dengue. In his final
- FONT SIZE
AbcSmall
AbcMedium
AbcLarge
Uh-oh! This is an exclusive story available for selected readers only.
Worry not. You’re just a step away.
Why ?
Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors
Stock analysis. Market Research. Industry Trends on 4000+ Stocks
Clean experience with
Minimal Ads
Comment & Engage with ET Prime community 
Exclusive invites to Virtual Events with Industry Leaders 
A trusted team of Journalists & Analysts who can best filter signal from noise 
Get 1 Year Complimentary Subscription of TOI+ worth Rs.799/-
